

ACVR1 Conjugated Antibody

Catalog No: #C43627

Package Size: #C43627-AF350 100ul #C43627-AF405 100ul #C43627-AF488 100ul #C43627-AF555 100ul #C43627-AF594 100ul #C43627-AF647 100ul #C43627-AF680 100ul #C43627-AF750 100ul #C43627-Biotin 100ul #C43627-Conjugated 50ul

Orders: order@signalwayantibody.com
Support: tech@signalwayantibody.com

Description

Product Name	ACVR1 Conjugated Antibody
Host Species	Rabbit
Clonality	Polyclonal
Applications	WB, IF
Species Reactivity	Hu Ms Rt
Specificity	The antibody detects endogenous levels of total ACVR1 protein.
Immunogen Description	Synthetic peptide of human ACVR1
Conjugates	Biotin AF350 AF405 AF488 AF555 AF594 AF647 AF680 AF750
Other Names	FOP;ALK2;SKR1;TSRI;ACTRI;ACVR1A;ACVRLK2
Accession No.	Swiss-Prot#:Q04771NCBI Gene ID:90NCBI mRNA#:NCBI Protein#:NP_001096
Calculated MW	57
Formulation	0.01M Sodium Phosphate, 0.25M NaCl, pH 7.6, 5mg/ml Bovine Serum Albumin, 0.02% Sodium Azide
Storage	Store at 4°C in dark for 6 months

Application Details

WB: 1:50-1:200

IF: 1:50-1:200

Background

Activins are dimeric growth and differentiation factors which belong to the transforming growth factor-beta (TGF-beta) superfamily of structurally related signaling proteins. Activins signal through a heteromeric complex of receptor serine kinases which include at least two type I (I and IB) and two type II (II and IIB) receptors. These receptors are all transmembrane proteins, composed of a ligand-binding extracellular domain with cysteine-rich region, a transmembrane domain, and a cytoplasmic domain with predicted serine/threonine specificity. Type I receptors are essential for signaling; and type II receptors are required for binding ligands and for expression of type I receptors. Type I and II receptors form a stable complex after ligand binding, resulting in phosphorylation of type I receptors by type II receptors. This gene encodes activin A type I receptor which signals a particular transcriptional response in concert with activin type II receptors. Mutations in this gene are associated with fibrodysplasia ossificans progressive.

Published Papers

el at., Enhancing the regenerative effectiveness of growth factors by local inhibition of interleukin-1 receptor signaling. In Sci Adv on 2020 Jun 12 by Ziad Julier, Rezvan Karami, et al..PMID:32582857, , (2020)

[PMID:32582857](https://pubmed.ncbi.nlm.nih.gov/32582857/)

Note: This product is for in vitro research use only and is not intended for use in humans or animals.